Cytokinetics
CYTK
61.12
-0.23
-0.37%
Cytokinetics
US · CYTK
#1564 by market cap
Listed 1970
61.12
-0.23
-0.37%
Live - 5344 symbols - heartbeat 340s ago
· 2026-10-08 08:22
Pre-market
60.75
-0.61%
After-hours
61.12
0.00%
- Market cap
- 8.50B
- P/E (TTM)i
- -8.47
- P/Bi
- -48.97
- EPSi
- -6.54
- Div yieldi
- 0.00%
- 52W posi
- 20%
Reader sentiment
Are you bullish or bearish on CYTK?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.4 percentage points.
Institutional ownership
- Held by institutions
- 116.57% -0.36pp
- Institutions
- 562 -1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund85.32%
Hedge Fund18.28%
Public Company5.26%
Private Company2.91%
VC/PE Fund2.72%
Government Pension Fund0.90%
Sovereign Wealth Fund0.73%
Insurance Company0.35%
Individual/Insider0.34%
Top holders as of 2026-06-30
T. Rowe Price Group, Inc.
14.87% · 20.68M sh
BlackRock
14.45% · 20.09M sh
Vanguard Capital Management, LLC
5.05% · 7.02M sh
Wellington Management Group
4.99% · 6.93M sh
Vanguard Portfolio Management, LLC
4.83% · 6.71M sh
State Street Global Advisors
4.67% · 6.49M sh
FMR
3.61% · 5.01M sh
Avoro Capital Advisors LLC
3.60% · 5.00M sh
Bank of America Corporation
3.19% · 4.43M sh
Geode Capital Management, LLC
2.67% · 3.71M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 21 buys · 29 sells
| Name | Role | Stake |
|---|---|---|
| Robert Blum | Chief Executive Officer | 0.09% |
| Fady Malik | Officer | 0.07% |
| John Henderson | Independent Chairperson | 0.06% |
| Wendell Wierenga | Independent Director | 0.03% |
| Nancy Wysenski | Independent Director | 0.02% |
| Muna Bhanji | Independent Director | 0.02% |
| Robert Harrington | Independent Director | 0.02% |
| Sung Lee | Chief Financial Officer | 0.01% |
| B. Parshall | Independent Director | 0.01% |
| Edward Kaye | Independent Director | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-27 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–65.46 |
| 2026-09-21 | Fady Malik | Officer | Derivative Exercise and Sale | -3,500 | $7.80–68.29 |
| 2026-09-14 | Robert Blum | Chief Executive Officer | Open Market Disposition | -97,926 | $69.33 |
| 2026-09-14 | Robert Landry | Director | Open Market Disposition | -1,000 | $72.13 |
| 2026-09-13 | Robert Blum | Chief Executive Officer | Other Acquisition | +97,926 | -- |
| 2026-09-13 | Robert Blum | Chief Executive Officer | Other Disposition | -99,276 | -- |
| 2026-09-13 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–73.44 |
| 2026-09-10 | Robert Landry | Director | Open Market Disposition | -1,000 | $74.66 |
| 2026-09-07 | Fady Malik | Officer | Derivative Exercise and Sale | -3,500 | $7.80–75.46 |
| 2026-08-31 | B. Parshall | Independent Director | Open Market Disposition | -5,000 | $71.48 |
| 2026-08-30 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–70.24 |
| 2026-08-30 | Andrew Callos | Executive Vice President | Derivative Exercise and Sale | -10,000 | $23.26–70.24 |
| 2026-08-17 | Fady Malik | Officer | Derivative Exercise and Sale | -3,500 | $7.80–75.82 |
| 2026-08-09 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–76.76 |
| 2026-07-29 | Andrew Callos | Executive Vice President | Derivative Exercise and Sale | -14,000 | $23.26–79.88 |
| 2026-07-26 | Robert Blum | Chief Executive Officer | Derivative Exercise and Sale | -7,500 | $10.60–80.87 |
| 2026-07-20 | Fady Malik | Officer | Derivative Exercise and Sale | -3,500 | $7.80–80.59 |
| 2026-07-14 | Wendell Wierenga | Independent Director | Other Acquisition | +75 | $82.62 |
| 2026-07-14 | Nancy Wysenski | Independent Director | Other Acquisition | +75 | $82.62 |
| 2026-07-14 | John Henderson | Independent Chairperson | Other Acquisition | +272 | $82.62 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:22:52 · For reference only, not investment advice and not tailored to your situation.